

Table 3. Progression free survival, overall survival and adverse events

	Panitumumab	Trifluridine- tipiracil + bevacizumab	Regorafenib	Best supportive care
	Intervention	Comparator 3rd line	Comparator 4th line	Comparator 5th line
Progression free survival (months)	3.69	5.60	2.18	unknown
Overall survival (months)	12.67	10.80	6.91	4
Adverse events ≥ grade 3* (% patients)	22.0%	72.4%	51.6%	unknown
References	CHRONOS ²	SUNLIGHT ²⁷	CORRECT and CONCUR ^{28,29}	Clinical expert opinion

*The cost of adverse events is not included in the cost analysis.